Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation

Yiyan Zheng, Ritika Sethi, Lingegowda S. Mangala, Charlotte Taylor, Juliet Goldsmith, Ming Wang, Kenta Masuda, Mohammad Karaminejadranjbar, David Mannion, Fabrizio Miranda, Sandra Herrero-Gonzalez, Karin Hellner, Fiona Chen, Abdulkhaliq Alsaadi, Ashwag Albukhari, Donatien Chedom Fotso, Christopher Yau, Dahai Jiang, Sunila Pradeep, Cristian Rodriguez-AguayoGabriel Lopez-Berestein, Stefan Knapp, Nathanael S. Gray, Leticia Campo, Kevin A. Myers, Sunanda Dhar, David Ferguson, Robert C. Bast, Anil K. Sood, Frank Von Delft, Ahmed Ashour Ahmed

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Though used widely in cancer therapy, paclitaxel only elicits a response in a fraction of patients. A strong determinant of paclitaxel tumor response is the state of microtubule dynamic instability. However, whether the manipulation of this physiological process can be controlled to enhance paclitaxel response has not been tested. Here, we show a previously unrecognized role of the microtubule-associated protein CRMP2 in inducing microtubule bundling through its carboxy terminus. This activity is significantly decreased when the FER tyrosine kinase phosphorylates CRMP2 at Y479 and Y499. The crystal structures of wild-type CRMP2 and CRMP2-Y479E reveal how mimicking phosphorylation prevents tetramerization of CRMP2. Depletion of FER or reducing its catalytic activity using sub-therapeutic doses of inhibitors increases paclitaxel-induced microtubule stability and cytotoxicity in ovarian cancer cells and in vivo. This work provides a rationale for inhibiting FER-mediated CRMP2 phosphorylation to enhance paclitaxel on-target activity for cancer therapy.

Original languageEnglish
Article number476
JournalNature communications
Volume9
Issue number1
DOIs
Publication statusPublished - 2018 Dec 1
Externally publishedYes

Fingerprint

phosphorylation
Phosphorylation
Paclitaxel
Microtubules
therapy
Tuning
cancer
tuning
Neoplasms
tyrosine
determinants
inhibitors
catalytic activity
manipulators
Physiological Phenomena
depletion
Therapeutics
tumors
Microtubule-Associated Proteins
proteins

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Zheng, Y., Sethi, R., Mangala, L. S., Taylor, C., Goldsmith, J., Wang, M., ... Ahmed, A. A. (2018). Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nature communications, 9(1), [476]. https://doi.org/10.1038/s41467-017-02811-7

Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. / Zheng, Yiyan; Sethi, Ritika; Mangala, Lingegowda S.; Taylor, Charlotte; Goldsmith, Juliet; Wang, Ming; Masuda, Kenta; Karaminejadranjbar, Mohammad; Mannion, David; Miranda, Fabrizio; Herrero-Gonzalez, Sandra; Hellner, Karin; Chen, Fiona; Alsaadi, Abdulkhaliq; Albukhari, Ashwag; Fotso, Donatien Chedom; Yau, Christopher; Jiang, Dahai; Pradeep, Sunila; Rodriguez-Aguayo, Cristian; Lopez-Berestein, Gabriel; Knapp, Stefan; Gray, Nathanael S.; Campo, Leticia; Myers, Kevin A.; Dhar, Sunanda; Ferguson, David; Bast, Robert C.; Sood, Anil K.; Von Delft, Frank; Ahmed, Ahmed Ashour.

In: Nature communications, Vol. 9, No. 1, 476, 01.12.2018.

Research output: Contribution to journalArticle

Zheng, Y, Sethi, R, Mangala, LS, Taylor, C, Goldsmith, J, Wang, M, Masuda, K, Karaminejadranjbar, M, Mannion, D, Miranda, F, Herrero-Gonzalez, S, Hellner, K, Chen, F, Alsaadi, A, Albukhari, A, Fotso, DC, Yau, C, Jiang, D, Pradeep, S, Rodriguez-Aguayo, C, Lopez-Berestein, G, Knapp, S, Gray, NS, Campo, L, Myers, KA, Dhar, S, Ferguson, D, Bast, RC, Sood, AK, Von Delft, F & Ahmed, AA 2018, 'Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation', Nature communications, vol. 9, no. 1, 476. https://doi.org/10.1038/s41467-017-02811-7
Zheng, Yiyan ; Sethi, Ritika ; Mangala, Lingegowda S. ; Taylor, Charlotte ; Goldsmith, Juliet ; Wang, Ming ; Masuda, Kenta ; Karaminejadranjbar, Mohammad ; Mannion, David ; Miranda, Fabrizio ; Herrero-Gonzalez, Sandra ; Hellner, Karin ; Chen, Fiona ; Alsaadi, Abdulkhaliq ; Albukhari, Ashwag ; Fotso, Donatien Chedom ; Yau, Christopher ; Jiang, Dahai ; Pradeep, Sunila ; Rodriguez-Aguayo, Cristian ; Lopez-Berestein, Gabriel ; Knapp, Stefan ; Gray, Nathanael S. ; Campo, Leticia ; Myers, Kevin A. ; Dhar, Sunanda ; Ferguson, David ; Bast, Robert C. ; Sood, Anil K. ; Von Delft, Frank ; Ahmed, Ahmed Ashour. / Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. In: Nature communications. 2018 ; Vol. 9, No. 1.
@article{0ed75965dd6b4d7eb237fd12dfd7a760,
title = "Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation",
abstract = "Though used widely in cancer therapy, paclitaxel only elicits a response in a fraction of patients. A strong determinant of paclitaxel tumor response is the state of microtubule dynamic instability. However, whether the manipulation of this physiological process can be controlled to enhance paclitaxel response has not been tested. Here, we show a previously unrecognized role of the microtubule-associated protein CRMP2 in inducing microtubule bundling through its carboxy terminus. This activity is significantly decreased when the FER tyrosine kinase phosphorylates CRMP2 at Y479 and Y499. The crystal structures of wild-type CRMP2 and CRMP2-Y479E reveal how mimicking phosphorylation prevents tetramerization of CRMP2. Depletion of FER or reducing its catalytic activity using sub-therapeutic doses of inhibitors increases paclitaxel-induced microtubule stability and cytotoxicity in ovarian cancer cells and in vivo. This work provides a rationale for inhibiting FER-mediated CRMP2 phosphorylation to enhance paclitaxel on-target activity for cancer therapy.",
author = "Yiyan Zheng and Ritika Sethi and Mangala, {Lingegowda S.} and Charlotte Taylor and Juliet Goldsmith and Ming Wang and Kenta Masuda and Mohammad Karaminejadranjbar and David Mannion and Fabrizio Miranda and Sandra Herrero-Gonzalez and Karin Hellner and Fiona Chen and Abdulkhaliq Alsaadi and Ashwag Albukhari and Fotso, {Donatien Chedom} and Christopher Yau and Dahai Jiang and Sunila Pradeep and Cristian Rodriguez-Aguayo and Gabriel Lopez-Berestein and Stefan Knapp and Gray, {Nathanael S.} and Leticia Campo and Myers, {Kevin A.} and Sunanda Dhar and David Ferguson and Bast, {Robert C.} and Sood, {Anil K.} and {Von Delft}, Frank and Ahmed, {Ahmed Ashour}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41467-017-02811-7",
language = "English",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation

AU - Zheng, Yiyan

AU - Sethi, Ritika

AU - Mangala, Lingegowda S.

AU - Taylor, Charlotte

AU - Goldsmith, Juliet

AU - Wang, Ming

AU - Masuda, Kenta

AU - Karaminejadranjbar, Mohammad

AU - Mannion, David

AU - Miranda, Fabrizio

AU - Herrero-Gonzalez, Sandra

AU - Hellner, Karin

AU - Chen, Fiona

AU - Alsaadi, Abdulkhaliq

AU - Albukhari, Ashwag

AU - Fotso, Donatien Chedom

AU - Yau, Christopher

AU - Jiang, Dahai

AU - Pradeep, Sunila

AU - Rodriguez-Aguayo, Cristian

AU - Lopez-Berestein, Gabriel

AU - Knapp, Stefan

AU - Gray, Nathanael S.

AU - Campo, Leticia

AU - Myers, Kevin A.

AU - Dhar, Sunanda

AU - Ferguson, David

AU - Bast, Robert C.

AU - Sood, Anil K.

AU - Von Delft, Frank

AU - Ahmed, Ahmed Ashour

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Though used widely in cancer therapy, paclitaxel only elicits a response in a fraction of patients. A strong determinant of paclitaxel tumor response is the state of microtubule dynamic instability. However, whether the manipulation of this physiological process can be controlled to enhance paclitaxel response has not been tested. Here, we show a previously unrecognized role of the microtubule-associated protein CRMP2 in inducing microtubule bundling through its carboxy terminus. This activity is significantly decreased when the FER tyrosine kinase phosphorylates CRMP2 at Y479 and Y499. The crystal structures of wild-type CRMP2 and CRMP2-Y479E reveal how mimicking phosphorylation prevents tetramerization of CRMP2. Depletion of FER or reducing its catalytic activity using sub-therapeutic doses of inhibitors increases paclitaxel-induced microtubule stability and cytotoxicity in ovarian cancer cells and in vivo. This work provides a rationale for inhibiting FER-mediated CRMP2 phosphorylation to enhance paclitaxel on-target activity for cancer therapy.

AB - Though used widely in cancer therapy, paclitaxel only elicits a response in a fraction of patients. A strong determinant of paclitaxel tumor response is the state of microtubule dynamic instability. However, whether the manipulation of this physiological process can be controlled to enhance paclitaxel response has not been tested. Here, we show a previously unrecognized role of the microtubule-associated protein CRMP2 in inducing microtubule bundling through its carboxy terminus. This activity is significantly decreased when the FER tyrosine kinase phosphorylates CRMP2 at Y479 and Y499. The crystal structures of wild-type CRMP2 and CRMP2-Y479E reveal how mimicking phosphorylation prevents tetramerization of CRMP2. Depletion of FER or reducing its catalytic activity using sub-therapeutic doses of inhibitors increases paclitaxel-induced microtubule stability and cytotoxicity in ovarian cancer cells and in vivo. This work provides a rationale for inhibiting FER-mediated CRMP2 phosphorylation to enhance paclitaxel on-target activity for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=85041609909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041609909&partnerID=8YFLogxK

U2 - 10.1038/s41467-017-02811-7

DO - 10.1038/s41467-017-02811-7

M3 - Article

C2 - 29396402

AN - SCOPUS:85041609909

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 476

ER -